Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹582.11 Cr |
| Fresh Issue | ₹500.00 Cr |
| Offer for Sale | ₹82.11 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹372.00-391.00 per share |
| Discount | Retail: 0.00,Employee: 0.00 |
| BSE Code | 544319 |
| NSE Code | SENORES |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Ambit Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 38 shares and in multiples thereof
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.
The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.
The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.
The company's manufacturing unit is situated in Ahmedabad, Gujrat.
Competitive Strength
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | 107.00 |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company | 73.48 |
| 3 | Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | 20.22 |
| 4 | Funding the working capital requirements of the Company | 43.26 |
| 5 | Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | 59.48 |
| 6 | Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | 154.37 |
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt / Equity | 1.07% |
| RoNW | 23.60% |
| PAT Margin | 15.25% |
| Price to Book Value | 5.84 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 9.83 | 13.86 |
| P/E (x) | 39.77 | 28.21 |
| Promoter Holding | 66.67% | 45.77% |
| Market Cap | ₹1350.70 Cr. | |
